Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

Abiomed Inc., solvency ratios (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30).


The financial data reveals a limited but consistent profile in the leverage ratios over the observed periods. The debt-related metrics were only recorded in the earlier quarters of 2017, showing a very low level of debt relative to equity, capital, and assets.

Debt to Equity
The ratio remained constant at 0.03 in the two reported periods, indicating minimal reliance on debt compared to shareholder equity during the first half of 2017.
Debt to Capital
Similarly, this ratio held steady at 0.03, reflecting a stable capital structure with debt making up a small proportion of total capital in the same timeframe.
Debt to Assets
The ratio was 0.02 consistently in the two available periods, underscoring low indebtedness relative to total assets, suggesting a conservative approach to financing.
Financial Leverage
Measured over multiple quarters from mid-2017 through late 2022, financial leverage hovered slightly above 1.10, varying from 1.15 in the earliest recorded quarter to 1.10 in the latest. This indicates a stable use of total assets relative to equity with minimal fluctuation. The slight downward trend implies gradual de-leveraging or equity growth outpacing asset increases.

Overall, the company exhibits a conservative financial structure, characterized by very low debt levels and stable financial leverage. The absence of recorded debt data beyond 2017 might imply either a negligible debt position or limited disclosures in those periods. The financial leverage ratio's stability suggests consistent management of assets and equity without significant changes in financial risk exposure.


Debt Ratios


Debt to Equity

Abiomed Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017
Selected Financial Data (US$ in thousands)
Current portion of capital lease obligation
Capital lease obligation, net of current portion
Total debt
 
Stockholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30).

1 Q2 2023 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The financial data indicates a limited presence of total debt, with values reported only for the first two quarters of 2017, standing at approximately $16.15 million and $15.96 million respectively, after which no further debt amounts are recorded. This suggests either full repayment or reclassification of debt subsequent to September 2017.

Stockholders' equity demonstrates a consistent upward trend throughout the entire period from June 2017 to September 2022. Starting at approximately $567 million in mid-2017, the equity base expands steadily, exceeding $1.5 billion by the third quarter of 2022. This growth reflects sustained equity accumulation, possibly driven by retained earnings, capital injections, or valuation increases in assets.

The debt to equity ratio is available only for the first two quarters of the period and remains very low at 0.03. This low leverage ratio, combined with the absence of subsequent debt, indicates a strong equity position relative to debt, highlighting a conservative capital structure during this timeframe.

Overall, the financial trends suggest a solid and growing equity foundation with minimal reliance on debt financing. The stable and increasing equity levels denote financial strength and potential capacity for future investments funded through equity or internally generated funds.


Debt to Capital

Abiomed Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017
Selected Financial Data (US$ in thousands)
Current portion of capital lease obligation
Capital lease obligation, net of current portion
Total debt
Stockholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30).

1 Q2 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


Total Debt
The total debt figures are only available for the first two quarters, showing a slight decrease from 16,154 thousand US dollars on June 30, 2017, to 15,961 thousand US dollars on September 30, 2017. After these periods, no debt data is reported, which could indicate either the absence of debt or missing disclosure in subsequent quarters.
Total Capital
Total capital demonstrates a consistent upward trend from June 30, 2017, through September 30, 2022. Starting at 583,198 thousand US dollars, capital increases steadily over time, reaching 1,539,787 thousand US dollars by the last reported quarter. This growth suggests an ongoing expansion of the company's capital base over the observed period.
Debt to Capital Ratio
The debt to capital ratio is only reported for the first two quarters in 2017, remaining constant at 0.03. Given the absence of debt data and ratio figures for the remaining periods, it is not possible to assess how leverage evolved during the subsequent quarters. The initial low ratio indicates modest leverage relative to the capital base at that time.

Debt to Assets

Abiomed Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017
Selected Financial Data (US$ in thousands)
Current portion of capital lease obligation
Capital lease obligation, net of current portion
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30).

1 Q2 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The financial data reveals several key trends in the company's balance sheet items over the examined quarterly periods.

Total Debt
The total debt reported was approximately $16.2 million and $16.0 million in the first two quarters of the data presented (mid-2017). Subsequent quarters show no recorded debt values, indicating either full repayment, reclassification, or absence of new debt issuance during the remaining periods.
Total Assets
Total assets exhibited a consistent upward trajectory throughout the entire period analyzed, increasing from roughly $652 million in June 2017 to about $1.70 billion by September 2022. The growth was steady with no notable declines, suggesting ongoing asset accumulation, likely driven by investments, retained earnings, or operational expansion.
Debt to Assets Ratio
The ratio was steady at 0.02 for the two initial quarters reported, aligning with the presence of total debt and asset levels at that time. Absence of further ratio data correlates with the lack of reported debt, indicating a minimal or negligible debt burden relative to assets in later periods.

Overall, the company's financial position appears to have strengthened through substantial asset growth across multiple years while maintaining a very low debt level. This suggests a conservative capital structure with possible reliance on equity or internal financing, thus reducing financial risk associated with leverage. The continuous asset buildup likely supports expanded operational capacity or strategic investments.


Financial Leverage

Abiomed Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017
Selected Financial Data (US$ in thousands)
Total assets
Stockholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30).

1 Q2 2023 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


Total Assets

The total assets demonstrate a consistent upward trend throughout the periods analyzed. Starting at approximately 652 million US dollars in mid-2017, the assets increased steadily to reach over 1.7 billion US dollars by late 2022. This growth reflects ongoing expansion and accumulation of resources over the nearly five-year timeframe, with no significant declines or volatility observed.

Stockholders’ Equity

Stockholders' equity also exhibits a persistent increase over the examined quarters, beginning at around 567 million US dollars in June 2017 and rising to approximately 1.54 billion US dollars by September 2022. While the growth is fairly consistent, some minor fluctuations appear, such as a slight dip in the third quarter of 2019 and again in early 2021, but the general trajectory remains positive, indicating strengthened equity base and retained earnings accumulation over time.

Financial Leverage

The financial leverage ratio remains relatively stable throughout the period, fluctuating narrowly between 1.10 and 1.15. This narrow range suggests a conservative and steady approach to the company’s capital structure, with a slight gradual decrease in leverage evident towards the end of the timeframe. Maintaining leverage close to 1.1 implies limited reliance on debt financing relative to equity, supporting a stable financial risk profile.

Overall Assessment

The company shows robust asset growth accompanied by a proportional increase in stockholders’ equity, suggesting effective management of resources and retained earnings. The steady and low leverage ratio corroborates a cautious financing strategy, focusing more on equity than on debt. No abrupt changes or financial stresses are visible in the reviewed data, reflecting a stable financial condition and a consistent expansion pattern.